Tag Archives: Phil Nadeau

Cowen & Co. Maintains Their Buy Rating on Dynavax

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Dynavax (NASDAQ: DVAX), with a price target of $30. The company’s shares closed yesterday at $17.40. According to TipRanks.com, Nadeau is a 5-star analyst

Cowen & Co. Assigns a Hold Rating on Regeneron

In a report released today, Phil Nadeau from Cowen & Co. assigned a Hold rating to Regeneron (NASDAQ: REGN), with a price target of $450. The company’s shares opened today at $338.80, close to its 52-week low of $319.50. According

Cowen & Co. Thinks Syros Pharmaceuticals’ Stock is Going to Recover

In a report released today, Phil Nadeau from Cowen & Co. assigned a Buy rating to Syros Pharmaceuticals (NASDAQ: SYRS). The company’s shares opened today at $8.45, close to its 52-week low of $6.30. According to TipRanks.com, Nadeau is a

Cowen & Co. Reaffirms Their Buy Rating on Vertex Pharmaceuticals

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) on December 8 and set a price target of $200. The company’s shares closed on Friday at $143.61. According to TipRanks.com, Nadeau is a 4-star

Cowen & Co. Reiterates Their Buy Rating on Acorda Therapeutics

Cowen & Co. analyst Phil Nadeau reiterated a Buy rating on Acorda Therapeutics (NASDAQ: ACOR) on November 15 and set a price target of $30. The company’s shares closed yesterday at $17.25. According to TipRanks.com, Nadeau is a 4-star analyst

Myovant Sciences Gets a Buy Rating from Cowen & Co.

Cowen & Co. analyst Phil Nadeau assigned a Buy rating to Myovant Sciences (NYSE: MYOV) on November 13. The company’s shares closed yesterday at $13.43. Nadeau observed: “Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance